LSI Europe

“Sometimes those technologies need to be looked at from the needs perspective. Why would the end customer be willing to adopt it; why would a physician want to change their current practice and standard of care?” said Beatriz Volckaert Almansa, Investment Director at Philips Ventures. Her insight underlines a crucial consideration for investors and entrepreneurs alike: technology alone is not enough; it must align with real-world needs. From the importance of identifying market demand early to structuring strong teams and strategic partnerships, the discussion provided a wealth of actionable insights for medtech innovators looking to navigate the complexities of technology transfer. Originally published at: https://www.lsieuropesummit.com/news/technology-transfer-in-medtech-the-path-to-successful-investments

This Signature took place at LSI Europe ‘25 Emerging Medtech Summit in London. Join industry leaders Roger Brooks, Oern Stuge, and Samuel Levy as they examine the evolution and impact of OrganOx in the organ transplantation field, sharing insights on Terumo's $1.5 billion acquisition of OrganOx. Visit here: https://www.youtube.com/watch?v=Nw9ncVZPhpQ

In the medtech world, a “no” from an investor isn’t always what it seems. The decision to pass on a startup often comes down to more than just the technology—it’s a balancing act of risk, timing, and fit. And for the investors themselves, building a smart portfolio means getting comfortable with saying no—a lot. The Risk-Reward Dance The heart of the conversation revolved around a common challenge: how do medtech investors decide when a startup is worth the risk? Diana shared her experience passing on SIA during its Series A round. Despite FDA 510(k) clearance and a ready-to-launch product, she flagged a lack of clinical data and market validation. “It was all unknown,” she said. “Even though the product was approved, the addressable market size was unclear. That was perceived as a big risk.” Visit here: https://www.yumpu.com/en/document/view/70881036/medtech-portfolio-optimization-why-investors-say-no